DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Quantitative Nodal Burden as a Determinant Identifying Ampullary Adenocarcinoma Patients Benefiting From Adjuvant Chemotherapy

Recruiting

Conditions: Ampullary Adenoma
Chemotherapy Effect

First Posted Date: 2024-05-30

Last Posted Date: 2024-05-30

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 300

Registration Number: NCT06435767

Locations: 🇨🇳
Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/ National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Phase 2

Recruiting

Conditions: Immunotherapy
Esophageal Cancer
Chemotherapy
Nimotuzumab
Chemoradiotherapy

Interventions: Combination Product: Nimotuzumab with chemoradiotherapy

First Posted Date: 2024-05-28

Last Posted Date: 2024-05-28

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 55

Registration Number: NCT06429839

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

Phase 2

Recruiting

Conditions: Esophagus Cancer

Interventions: Combination Product: Tislelizumab (BGB-A317) with chemoradiotherapy

First Posted Date: 2024-05-28

Last Posted Date: 2024-12-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT06430658

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

Phase 2

Recruiting

Conditions: Chemoradiotherapy
Induction Therapy
Esophageal Cancer
Immunotherapy
Surgery

Interventions: Drug: Cardonilizumab
Radiation: Chemoradiotherapy ±immunotherapy
Procedure: Radical surgery

First Posted Date: 2024-05-20

Last Posted Date: 2024-05-20

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06421376

Locations: 🇨🇳
Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer

Phase 2

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: Serplulimab
Drug: Carboplatin
Drug: Cisplatin
Radiation: Brachytherapy and External Beam Radiotherapy

First Posted Date: 2024-05-17

Last Posted Date: 2024-05-17

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 240

Registration Number: NCT06419673

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Phase 2

Not yet recruiting

Conditions: Pleural Mesothelioma

Interventions: Drug: Cadonilimab Combined with chemotherapy

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 59

Registration Number: NCT06416930

Toripalimab for High-risk Locally Advanced Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancers

Interventions: Drug: Toripalimab

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 130

Registration Number: NCT06416696

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: Fruquintinib
Drug: PD-1inhibitor
Drug: albumin paclitaxel

First Posted Date: 2024-05-16

Last Posted Date: 2025-01-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06417892

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Phase 2

Recruiting

Conditions: TP53 Mutation
Endometrial Carcinoma
Recurrent or Metastatic

Interventions: Drug: Fluzoparib
Drug: paclitaxel (albumin bound)
Drug: Camrelizumab
Drug: Carboplatin injection
Drug: Carboplatin
Radiation: External irradiation

First Posted Date: 2024-05-14

Last Posted Date: 2024-05-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 117

Registration Number: NCT06413992

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: SHR-A1811+Adebrelimab

First Posted Date: 2024-05-13

Last Posted Date: 2024-05-17

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT06411457

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy